Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck announces 52pc of Q1 2009 revenue from Europe

Lundbeck announces 52pc of Q1 2009 revenue from Europe

13th May 2009

Lundbeck has announced 52 per cent of its total revenue for the first quarter of 2009 was from European business.

The rise was driven by the treatments Azilect, Ebixa and Cipralex. Revenues for these products grew by 47, 16 and 13 per cent respectively.

At constant exchange rates, revenue from European markets increased by 12 per cent, which amounted to DKK 1,675 million (201.67 million pounds).

President and chief executive officer of the company Ulf Wiinberg remarked the firm had delivered on the strategic intent of becoming one of the biggest pharmaceutical companies in the world during the first three months of the year due to its acquisition of Ovation.

He said: “We are also pleased with the revenue performance delivering double digit growth in the quarter, where significant growth for our key products and principal markets has been maintained.”

Last month, the Food and Drug Administration’s Psychopharmacology Drug Advisory Committee declared Lundbeck’s Serdolect (sertindole) was effective to treat patients with schizophrenia.

Head of drug development at the company Anders Gersel Pedersen commented the firm would continue to work with the regulatory body on the new drug application for the medication.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.